Overall (N=2146) | CYP2C19*2 allele | p Value | ||
Non-carrier (N=1135) | Carrier (N=1011) | |||
Age (years) | 60.8±9.8 | 60.8±9.9 | 60.9±9.8 | 0.75 |
Male sex (%) | 1410 (65.7) | 738 (65.0) | 672 (66.5) | 0.48 |
BMI (kg/m2) | 24.8±3.0 | 24.9±2.9 | 24.8 (3.1) | 0.56 |
Risk factor (%) | ||||
Hypertension | 1287 (60.0) | 679 (59.8) | 608 (60.1) | 0.88 |
Dyslipidaemia | 996 (46.4) | 505 (44.5) | 491 (48.5) | 0.06 |
Diabetes mellitus | 643 (29.9) | 328 (28.9) | 315 (31.2) | 0.25 |
Current smoker | 530 (24.7) | 289 (25.5) | 241 (23.8) | 0.38 |
Clinical presentation (%) | ||||
Stable/unstable angina | 1705 (79.5) | 915 (80.6) | 790 (78.1) | 0.16 |
NSTEMI/STEMI | 441 (20.6) | 220 (19.4) | 221 (21.9) | |
Number of vessels (%) | ||||
Single | 874 (40.7) | 457 (40.3) | 417 (41.3) | 0.47 |
Double | 677 (31.6) | 371 (32.7) | 306 (30.3) | |
Triple | 595 (27.7) | 307 (27.1) | 288 (28.5) | |
Drug therapy during follow-up (%) | ||||
Statins | 1836 (85.6) | 965 (85.0) | 871 (86.2) | 0.46 |
β-blockers | 1568 (73.1) | 837 (73.7) | 731 (72.3) | 0.45 |
ACE inhibitors | 774 (36.1) | 412 (36.3) | 362 (35.8) | 0.81 |
Angiotensin receptor blockers | 791 (36.9) | 410 (36.1) | 381 (37.7) | 0.45 |
Calcium blockers | 789 (36.8) | 430 (37.9) | 359 (35.5) | 0.25 |
Proton-pump inhibitors | 94 (4.4) | 46 (4.1) | 48 (4.8) | 0.43 |
Vitamin K antagonists | 25 (1.5) | 13 (1.5) | 12 (1.6) | 0.87 |
Timing of loading dose relative to PCI | ||||
No loading, chronic user | 737 (34.3) | 410 (36.1) | 327 (32.3) | 0.16 |
Before PCI | 1375 (64.1) | 709 (62.5) | 666 (64.1) | |
During or after PCI | 34 (1.6) | 16 (1.4) | 18 (1.8) | |
Type B2/C lesion | 1612 (75.1) | 856 (75.4) | 756 (74.8) | 0.73 |
Type C lesion | 1253 (58.4) | 668 (58.9) | 585 (57.9) | 0.64 |
BMI, body mass index; NSTEMI, non-ST elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST elevation myocardial infarction.